摘要
目的明确红霉素微球对支原体感染Wistar大鼠的保护作用。方法以乳糖酸红霉素为阳性对照药物,选择红霉素微球低、中、高3个剂量组(0.1、0.5、1.2g·kg-1·d-1)对肺炎支原体感染大鼠进行治疗,连续给药6d,通过观察大鼠症状,测定肺指数以及观察肺部病变程度来评价红霉素微球对大鼠支原体肺炎的保护作用。结果大鼠感染后第5天开始出现明显症状,支原体感染组,未经治疗的大鼠症状持续存在,而给药组能逐渐恢复正常,所有实验鼠均未出现死亡;支原体感染对照组肺指数为1.75,较正常组的肺指数(0.98)明显增加(P<0.01);红霉素微球低、中、高3个剂量组大鼠的肺指数分别降至1.45、1.38、1.25;红霉素微球减轻了大鼠肺组织病变程度,并有量效关系。结论红霉素微球具有较好的体内抗支原体的活性。
Objective To evaluate the antimicrobial effects oferythromycin microspheres against Mycoplasma pneumoniae in rats. Methods With erythromycin lactobionate as the positive control, erythromycin microspheres at 3 non-toxic doses （0.1, 0.5, and 1.2 g·kg^-1·d^-1） were administered intragastrically for 6 consecutive days in Wistar rats with Mycoplasma pneumoniae infection. The general condition and lung index of the rats were observed and measured to assess the therapeutic effects of the treatments against Mycoplasma pneumonioe infection. Results The erythromycin microspheres at 0.1, 0.5, 1.2g·kg^-1·d^-1 significantly alleviated the symptoms of the rats infected with Mycoplasma pneumoniae and reduced the pulmonary index of the infected rats fi＇om 1.75 to 1.45, 1.38 and 1.25, respectively （P〈0.01）. An obvious dosage-effect relationship was noted between the dose of erythromycin microsphere and the tissue pathologies due to the infection. Conclusion Erythromycin microspheres possess strong activity against Mycoplasma pneumoniae in rats.
出处
《南方医科大学学报》
CAS
CSCD
北大核心
2008年第10期1875-1877,共3页
Journal of Southern Medical University
基金
广东省科技计划资助项目(2005B30101015)
广州市科技计划资助项目(2005Z3.E0541)
关键词
红霉素微球
支原体
WISTAR大鼠
erythromycin microspheres
Myc oplas map ne umoniae
Wistar rats
